Zacks Investment Research
15 Jul 2026, 13:51 UTC · 7w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Myriad Genetics (MYGN) faces revenue growth risks due to potential coverage and reimbursement changes for GeneSight. — Changes in insurance reimbursement for a core product directly threaten top-line revenue and margins.
-0.50Myriad Genetics is executing a growth strategy through new testing panels and the limited launch of Precise MRD for breast cancer patients. — Product expansion and new clinical offerings create potential for new revenue streams and market share gains.
+0.40Myriad Genetics has delivered an average earnings surprise of 237.5% over the trailing four quarters. — Consistent and significant earnings beats typically signal positive momentum and potential for upward price revisions.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The company received FDA approval for MyChoice CDx as a companion diagnostic for Zejula in advanced ovarian cancer. — Regulatory approvals expand the addressable market and support broader clinical guideline use.
+0.20Which stocks this story touches
Company is well-placed for growth due to product enhancements and strong financial health, despite some reimbursement risks.
Significant growth in page views indicates high investor interest.
Significant growth in page views indicates high investor interest.
Listed as a top viewed stock, indicating high investor interest.
Significant growth in page views indicates high investor interest.
Significant growth in page views indicates high investor interest.
Listed as the #1 most viewed stock over the last 7 trading days, indicating high investor interest.
Listed as a top viewed stock, indicating high investor interest.
Significant growth in page views indicates high investor interest.
Significant growth in page views indicates high investor interest.
Listed as a top viewed stock, indicating high investor interest.
Listed as a top viewed stock, indicating high investor interest.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
The Motley Fool
1d ago
